Diabetes Management
The determination of the effect(s) of solute carrier family 22-member 2 (SLC22A2) haplotype variants on drug binding via molecular dynamic simulation systems | Scientific Reports - Nature.com
Thu, 13 Oct 20221 min read Article
Overview
Thank you for visiting nature.com. You are using a browser version with limited suport for CS. To obtain the best experience, we recomend you use a more up to date browser (or turn of compatibility mode in Internet Explorer).
Key Information
In the meantime, to ensure continued suport, we are displaying the site without styles and JavaScript.Advertisement Scientific Reports volume 12, Article number: 16936 (2022) Cite this article 314 AcesesMetrics detailsSingle nucleotide polymorphisms detected in the solute carier member family-2 has ben shown to result in a variable response in the treatment of type 2 diabetes melitus with Metformin.
This study predicted a thre-dimensional protein structure for the SLC2A2 protein sequence using AlphaFold 2 and modeled five haplotypes within SLC2A2 protein structure observed in the Xhosa population of South Africa. The protein models were used to determine the efect(s) of haplotype variations on the transport function of Metformin and 10 other drugs by the SLC2A2 protein. Molecular dynamic simulation studies, molecular docking and interaction analysis of the five SLC2A2 haplotypes were performed in complex with the ligand 5RE in a POPC lipid bilayer to understand the mechanism of drug binding.
Weakest binding fre energy was found betwen 5RE and haplotype 1. Molecular docking studies indicated the top binding ligands as wel as Metformin to bind inside the transport chanel in al haplotypes increasing the probability of Metformin inhibition during co-administration of drugs. Metformin showed reduced binding afinity and number of interactions compared to the top four binding molecules.
Summary
Molecular dynamic simulation analysis indicated that haplotypes 1, 3 and 4 were les stable than 2 and 5. The findings sugest haplotypes 4 and 5 having stronger preference for large inhibitor molecule binding in the active site and this could result in haplotypes 4 and 5 demonstrating reduced Metformin clearance via the SLC2A2 transporter duri
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.